CompletedNCT00299715

Three doses of extended-release paliperidone or placebo for mania in bipolarity

About this title

A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder

Medication studyAges 18–65

The study in practice

Understand this study

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Study clarity

Study start dateFebruary 2006

Recruitment status: Completed
Enrollment listed in the registry: 473
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: From 18 Years to 65 Years
Official registry ID: NCT00299715
Official title: Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release Paliperidone in the Treatment of Subjects With Acute Manic and Mixed Episodes Associated With Bipolar I Disorder

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone extended-release.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.